Status:
COMPLETED
Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Centers for Disease Control and Prevention
Conditions:
Malaria
Eligibility:
All Genders
Brief Summary
The purpose of this study is to describe the pediatric and adult patients (U.S. and foreign residents) diagnosed with malaria and treated with artemether-lumefantrine with regard to their demographics...
Eligibility Criteria
Inclusion
- Any male or female infant, child or adult patient diagnosed with malaria who received artemether-lumefantrine and was reported to the CDC. Malaria may be clinically suspected or confirmed (microscopically, and/or by polymerase chain reaction \[PCR\], and/or rapid diagnostic test \[RDT\]).
Exclusion
- NA
Key Trial Info
Start Date :
May 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2015
Estimated Enrollment :
324 Patients enrolled
Trial Details
Trial ID
NCT01228344
Start Date
May 1 2010
End Date
September 30 2015
Last Update
April 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centers for Disease Control and Prevention,GA
Atlanta, Georgia, United States